ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 570

In Vivo Therapeutic Success Of Microrna-155 (miR-155) Antagomir In a Mouse Model Of Lupus Pulmonary Hemorrhage

Shiyu Zhou1, Dong Liang2, Xinfang Huang3, Chunyuan Xiao3, Yuanjia Tang1, Qian Jia3, John B. Harley4,5 and Nan Shen6,7,8, 1Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Shanghai Institute of Rheumatology, Shanghai Institute of Rheumatology ,Renji Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China, 4Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 5US Department of Veterans Affairs Medical Center, Cincinnati, OH, 6Rheumatology, Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, OH, China, 7Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, cincinnati, OH, 8Shanghai Institute of Rheumatology ,Renji Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Intervention, MicroRNA and SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: MiR-155 is a typical pleiotropic miRNA that participates in various aspects of immunity. Previous in vitro studies indicated that it is both a pro-inflammatory and an anti-inflammatory regulator. Furthermore, studies in multiple mouse models (LPS shock, EAE, and CIA) revealed a pathogenic role of this miRNA in the development of tissue damage. Also, miR-155 is abnormally overexpressed among different lupus mouse models. However, aspects of the role of miR-155 in lupus acute tissue damage remain unclear. In this study, we systemically examined the role of miR-155 in the development of pulmonary hemorrhage (PH) in Pristane-induced lupus, by assessing the effect of the administration of chemically modified complementary oligonucleotides of miR-155, called the miR-155 antagomir.

Methods:  Pristane-induced PH mouse model was established as previously reported. Briefly, miR-155 knockout (KO) and wild type (WT) control mice received a single i.p injection of 0.5 ml pristane. After 14 days, lung tissues were collected for pathologic assessment. The dynamic expression of miR-155 was evaluated 1, 3, 7, 14 days post Pristane injection. In intervention experiments, the mice were divided into two groups, receiving respectively three consecutive i.v injections of miR-155 antagomir (miRNA inhibitor) (n=5) or random sequence antagomir negative control (n=5) 3 days before Pristane injection. Two weeks later, the prevalence of PH was evaluated by H&E staining. Total lung RNAs were assayed by qPCR or subjected to gene profiling. Gene profiling data was analyzed by IPA software. Serum cytokines were messured by Bio-plex ProTM Assays. 

Results: We showed that miR-155 was elevated in lung tissues in the process of PH induced by Pristane. MiR-155 KO mice appeared to develop attenuated PH, with reduced levels of pro-inflammatory cytokines (TNF-a, IL-6, IL-1β) in sera and target tissues. IPA analysis of gene profiling data indicated that IL-6 signaling pathway was dramatically activated in WT mice but not in miR-155 KO mice 7 day post pristane injection. By integrating the gene expression profiling data from miR-155 KO mice with microRNA target predication, our data suggest that PPARα, an anti-inflammatory transcription factor, is a novel functional target of miR-155. Furthermore, we showed that in vivo silencing of miR-155 by a synthetic miRNA inhibitor­­­­—miR-155 antagomir significantly ameliorated PH induced by Pristane (miR-155 antagomir: 20% PH; random sequence antagomir negative control: 80% PH). Consistently, the pro-inflammatory cytokines (TNF-a, IL-6, IL-1β) were reduced upon miR-155 silencing. 

Conclusion: Overall, our study shows that knockdown of miR-155 by miR-155 antagomir inhibits Pristane induced PH through reducing the production of pro-inflammatory cytokines. This finding suggests a promising therapeutic potential of miR-155 antagonist in the treatment of acute lung inflammation in lupus and reinforces the conclusion that antagomir may prove to be a very effective general therapeutic strategy for human disease.


Disclosure:

S. Zhou,
None;

D. Liang,
None;

X. Huang,
None;

C. Xiao,
None;

Y. Tang,
None;

Q. Jia,
None;

J. B. Harley,
None;

N. Shen,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-vivo-therapeutic-success-of-microrna-155-mir-155-antagomir-in-a-mouse-model-of-lupus-pulmonary-hemorrhage/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology